drugset / Trial / NCT03843632

Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

NCT03843632

Phase 3 Completed 150 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.

Timeline

Start
2019-03-01
Primary completion
2020-06-19
Completion
2020-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Varivax Vaccine 0.5 ml Subcutaneous

Indications